New combo attack on inoperable lung cancer
NCT ID NCT02599454
Summary
This early-stage study tested a new combination treatment for patients with early-stage lung cancer who could not have surgery. It combined a targeted, high-dose radiation treatment with a drug (atezolizumab) designed to help the immune system fight cancer. The main goal was to find the safest dose and understand the side effects of using these two treatments together.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
David Grant United States Air Force Medical Center
Travis AFB, California, 94535-1800, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.